Results 161 to 170 of about 63,989 (248)

Population pharmacokinetics of rivaroxaban after transjugular intrahepatic portosystemic shunt. [PDF]

Eur J Clin Pharmacol
Jia M, Chai Y, Gao Y, Jing C, Zhu K, Zhu T, Wang L, Sun A, Yang J, Zhu Y, Feng Y, Cao Y, Li J.   +12 more
europepmc   +1 more source

The impact of body composition variability on coagulation monitoring in patients on direct oral factor Xa inhibitors for treatment of venous thromboembolism. [PDF]

Front Cardiovasc Med
Kurzmann-Guetl K, Leitner DR, Gary T, Avian A, Beck A, Rabensteiner J, Prueller F, Raggam RB, Brodmann M, Toplak H.   +9 more
europepmc   +1 more source

Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis. [PDF]

Res Pract Thromb Haemost
Almajdi A, Almutairi S, Alharbi M.
europepmc   +1 more source

Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? [PDF]

, 2014
Al-Khatib, SM, Banerjee, A, Blendea, D, Camm, AJ, Conroy, JM, Cosio, FG, De Bono, J, G Cosio, MD, Guasch, E, Halperin, JL, Hess, PL, Kirchhof, P, Lip, GY, Nattel, S, Ruskin, J, Savelieva, I   +15 more
core   +1 more source

Trend of Reported Bleeding in Warfarin Compared with Direct Oral Anticoagulants in Japan. [PDF]

Drug Healthc Patient Saf
Takami A, Terashima G, Tajima T, Yamashita K, Igarashi A.   +4 more
europepmc   +1 more source

Rivaroxaban treatment discontinuation rates in patients with nonvalvular atrial fibrillation in Italian clinical practice: RITMUS-AF. [PDF]

PLoS One
Pizzi C, Pagliani L, Carbonare LD, Agostoni P, Imbalzano E, Galasso G, Casella G, Dasseni N, De Luca L, Porto I, Sassone B, Tosarello D, Vora P, Erminero C, Forleo GB, Fusco P, Mauro C, Milone F, Perna GP.   +18 more
europepmc   +1 more source

Extended Anticoagulation Therapy With Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial. [PDF]

J Am Heart Assoc
Xiong W, Yamashita Y, Morimoto T, Muraoka N, Shioyama W, Nakagawa Y, Chatani R, Yamamoto H, Shibata T, Morikawa N, Fukumoto Y, Nishimoto Y, Ono K, Kimura T, ONCO PE Trial Investigators.   +14 more
europepmc   +1 more source

Accidental Rivaroxaban Intoxication in a 25-month-old Child Monitored by Thromboelastography: A Case Report. [PDF]

Kobe J Med Sci
Nakanishi K, Yamasaki S, Watanabe Y, Nakashima K, Nishihara T, Fujii J, Ohyama S, Yokoyama H, Yokoyama N.   +8 more
europepmc   +1 more source

Misdiagnosis of rivaroxaban-associated multiple intracranial hemorrhages as intracranial metastatic tumor: a case report. [PDF]

Front Med (Lausanne)
Xu F, Liu Q, Hua S, Yang S.
europepmc   +1 more source

Anticoagulants beyond coagulation: a narrative review of cardiovascular effects. [PDF]

Cardiovasc Res
Aarts A, Ten Cate H, Ten Cate-Hoek AJ.
europepmc   +1 more source